Oncocyte Publishes Study Demonstrating Predictive Potential for DetermaIO® Test in Triple Negative Breast Cancer

Author's Avatar
Sep 30, 2021

Data show that DetermaIO demonstrates superior accuracy compared to standard of care PD-L1 IHC for predicting a patient’s response to immunotherapy